✦ LIBER ✦

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four–week efficacy and safety results of a randomized, placebo-controlled study

✍ Scribed by Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G. Krueger; Dafna Gladman; Juan Gomez-Reino; Kim Papp; Julie Zrubek; Surekha Mudivarthy; Michael Mack; Sudha Visvanathan; Anna Beutler

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 124 KB
Volume: 60
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.24403

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erratum: Golimumab, a new human tumor ne

Erratum: Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four–week efficacy and safety results of a randomized, placebo-controlled study

✍ Arthur Kavanaugh; Iain McInnes; Philip Mease; Gerald G. Krueger; Dafna Gladman; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 31 KB 👁 1 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Erratum: Golimumab, a human anti-tumor n

Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views

Erratum: Golimumab, a new human anti–tum

Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Rituximab for rheumatoid arthritis refra

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

✍ Stanley B. Cohen; Paul Emery; Maria W. Greenwald; Maxime Dougados; Richard A. Fu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 2 views